### **Supplemental Figures**

Figure S1. In vitro cell growth inhibition assay with DXd.

Figure S2. Enhanced cytokine production by tumor-infiltrating immune cells by U3-1402 treatment.

Figure S3. Individual survival curves from the CD8<sup>+</sup> cells depletion experiment.

Figure S4. In vivo antitumor efficacy and ex vivo re-stimulation assay with DXd.

Figure S5. Antitumor effect of anti–PD-1 and U3-1402 therapy, and expression levels of effector/proliferation markers when the tumor burden is low.

Figure S6. In vivo treatment efficacy of U3-1402 and PD-1 inhibitor, and the characteristics of mouse HER3-expressing cancer cells.

Figure S7. Intra-tumoral MDSCs and Tregs density.

Figure S8. Enhanced cytokine production by tumor-infiltrating immune cells after combo treatment.

Figure S9. Evaluation of HER3 expression in immune cells.

Figure S10. Induced infiltration of myeloid cells and NK cells with U3-1402 treatment, and evaluation of TLR4 expression in intra-tumoral immune cells.

Figure S11. Representative figures for each immunohistochemical HER3 score.

Figure S12. OS curves based on HER3 positivity in the entire patient population, and HER3 scores of PD-1 inhibitor responders.







Figure S1. In vitro cell growth inhibition assay with DXd. Data represents the means  $\pm$  SEM of six replicates, and are representative of two independent experiments.











Figure S2. Enhanced cytokine production by tumor-infiltrating immune cells by U3-1402 treatment. (A, B and D) Flow cytometry analysis of the indicated cell types. Each dot represents one tumor. n = 6-7 for each arm. The *P* values are shown on horizontal lines. Data were assessed by unpaired t-test. (C) Representative images of interferon- $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) producing CD4<sup>+</sup> tumor-infiltrating lymphocytes (TILs) (left), and IFN- $\gamma$  and interleukin-2 (IL-2) producing CD4<sup>+</sup> TILs (right). Each value in the figures indicates the frequency of each cell type. NK, natural-killer.



#### Figure S3. Individual survival curves of CD8<sup>+</sup> cells depletion experiment.

n = 12 for each arm, pooled from 4 independent experiments. The treatment was initiated when tumor sizes reached 80–250 mm<sup>3</sup> (high tumor burden). CD8<sup>+</sup> cell depletion weakened U3-1402 treatment efficacy (right) although it did not affect natural tumor growth (left). Differences in survival curves were assessed using a log-rank test.






Figure S4. In vivo antitumor efficacy and Ex vivo re-stimulation assay with DXd.

(A) Left: Tumor volume curve of subcutaneous CM-3 tumors The treatment was initiated when tumor sizes reached 80–250 mm<sup>3</sup>. Right: Tumor volume 11 days after treatment initiation. n = 11 for each arm, pooled from two independent experiments. (B) Flow cytometry analysis of CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs). n = 6 for each arm. (C) Flow cytometry analysis of CD4<sup>+</sup> TILs. n = 6 for each arm. Each dot in A–C represents one tumor. The *P* values in A–C are shown on horizontal lines. Data were assessed by unpaired t-test. IFN- $\gamma$ , Interferon- $\gamma$ . TNF- $\alpha$ , Tumor necrosis factor- $\alpha$ . IL-2, interleukin-2.




# Figure S5. Antitumor effect of anti–PD-1 and U3-1402 therapy, and expression levels of effector/proliferation markers when the tumor burden is low.

(A) Tumor volume curve of subcutaneous CM-3 tumors. n = 7 for each arm, pooled from two independent experiments. The *P* values are shown on the right side of vertical lines. Data were assessed by unpaired t-test. The treatment was initiated when tumor sizes reached 40–80 mm<sup>3</sup>. These experiments were performed independently of those shown in Figure 2. The tumor volume curves were plotted until the first observed death. (**B** and **C**) Flow cytometry analysis of the indicated cell types based on tumor burdens (TBs). Low TB, 40–80 mm<sup>3</sup>. High TB, 80–250 mm<sup>3</sup>. n = 6 for each arm. The *P* values are shown on horizontal lines. Data were assessed by unpaired t-test. PD-1, programmed cell death-1. TILs, tumor-infiltrating lymphocytes. MFI, mean fluorescent intensity.



**Figure S6. In vivo treatment efficacy of U3-1402 and PD-1 inhibitor, and the characteristics of mouse HER3-expressing cancer cells.** (**A**) Body weight changes of mice during treatment. Left: n = 11 for each arm, pooled from four independent experiments with DBA/2NCrI mice carrying CM3 tumors. The treatment was initiated when tumor sizes reached  $80-250 \text{ mm}^3$ . Right: n = 14 for each arm, pooled from two independent experiments with C57BL/6J mice carrying B16-F10 tumors. The treatment was initiated when tumor sizes reached  $20-80 \text{ mm}^3$ . (**B**) Flow cytometry analysis of membranous HER3 expression of cultured cells. Images of membranous HER3 immunostaining of CM-3 tumor (top) and B16-F10 tumor (bottom). Scale bars,  $100 \mu$ m. Data and figures are representative of three independent experiments. (**C**) Left: Flow cytometry analysis of membranous programmed cell death-ligand 1 (PD-L1) expression. Data are representative of three independent experiments. Right: Non-synonymous tumor mutation burden (TMB) from whole exome sequencing analysis of fresh frozen tumor tissue. (**D**) Top: Tumor volume curve of subcutaneous B16-F10 tumors (left) and survival curve of B16-F10 tumor–carrying mice (right) treated as indicated. Bottom: Tumor volume at 11 days (left) or 14 days (right) after treatment initiation. n = 14 for each arm, pooled from two independent experiments. The *P* values are shown on horizontal lines only when they were < 0.05. \*\* or \*\*\* indicates *P* values < 0.01 or < 0.001, respectively. Data were assessed by unpaired t-test (**C** and **D**) or one-way ANOVA with Tukey's correction for multiple comparisons (**D**). Differences in survival curves were assessed using a log-rank test (**D**). PD-1, programmed cell death-1.



**Figure S7. Intra-tumoral MDSCs and Tregs density.** Flow cytometry analysis of the indicated cell types. Each dot represents one tumor. n = 16-22 for each arm, pooled from five independent experiments. MDSCs, myeloid-derived suppressor cells. Tregs, regulatory T cells. PD-1, programmed cell death-1.






Figure S8. Enhanced cytokine production by tumor-infiltrating immune cells after combo treatment.

(**A** and **B**) Flow cytometry analysis of the CD8<sup>+</sup> (**A**) and CD4<sup>+</sup> (**B**) tumor-infiltrating lymphocytes (TILs). Each dot represents one tumor. n = 9-10 for each arm. The *P* values are shown on horizontal lines only when they were < 0.05 in multiple comparisons. Data were assessed by one-way ANOVA with Tukey's correction for multiple comparisons. (**C**) Left: Flow cytometry analysis of the tumor-infiltrating natural killer (NK) cells. Each dot represents one tumor. n = 9-10 for each arm. The *P* values are shown on horizontal lines only when they were < 0.05 in multiple comparisons. Data were assessed by one-way ANOVA with Tukey's correction for multiple comparisons on horizontal lines only when they were < 0.05 in multiple comparisons. Data were assessed by one-way ANOVA with Tukey's correction for multiple comparisons. Right: Representative images of interferon- $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) producing tumor-infiltrating NK cells. Each value in the figures indicates the frequency of each cell type. PD-1, programmed cell death-1. IL-2, interleukin-2



В




#### Figure S9. Evaluation of HER3 expression in immune cells.

(A) Flow cytometry analysis of HER3 expression in the indicated cell types. n = 3-5 for each cell type. There are significant differences in HER3 expression between intra-tumoral CD45-negative/FSC-high cells including CM-3, and each immune cell in both tumors and the spleen (each *P* value is < 0.0001 in multiple comparisons: \*\*\*\*). (B) Representative images of mouse spleen staining. Left: Hematoxylin-eosin stain. Right: HER3 immunostaining. Scale bars, 100  $\mu$ m. NK, natural killer. FSC, forward scatter. Data were assessed by one-way ANOVA with Tukey's correction for multiple comparisons.

Α






### Membranous TLR4

## Figure S10. Induced infiltration of myeloid cells and NK cells with U3-1402 treatment, and evaluation of TLR4 expression in intra-tumoral immune cells.

(A) Flow cytometry analysis of the indicated cell types. Each dot represents one tumor. n = 7-8 for each arm. The *P* values are shown on horizontal lines. Data were assessed by unpaired t-test. (B) Flow cytometry analysis of membranous toll-like receptor 4 (TLR4) expression in the indicated cell types. Top: Histograms of fluorescence intensity of phycoerythrin (PE). Blue and red curves indicate the histograms of cells stained by PE-conjugated anti-TLR4 antibody and PE-conjugated isotype control antibody. Bottom: Scatter plots of the cells stained by the anti-TLR4 antibody or the corresponding isotype control antibody. Values in the figures indicates the frequency of TLR4<sup>+</sup> cells which was defined as phycoerythrin (PE)-positive cells. DC, dendritic cell. TAM, tumor-associated macrophage. NK, natural killer.



#### Figure S11. Representative figures for each immunohistochemical HER3 score.

HER3 staining was categorized by intensity as 0, 1+, 2+, and 3+. (A) 0, no staining or membrane staining in  $\leq$  10 % of the tumor cells; (B) 1+, a faint or barely perceptible incomplete membrane staining in > 10 % of tumor cells; (C) 2+, weak-to-moderate complete membrane staining observed in > 10 % of tumor cells; (D) 3+, circumferential membrane staining that is complete, intense, and in > 10 % of tumor cells. Scale bar, 100  $\mu$ m.




Figure S12. OS curves based on HER3 positivity in the entire patient population, and HER3 scores of PD-1 inhibitor responders.

(A) Kaplan-Meier curves for overall survival (OS) in HER3-positive or HER3-negative patients treated with programmed cell death-1 (PD-1) inhibitors. Vertical bars denote censoring. CI, confidence interval. A Difference in survival curves was assessed using a log-rank test. (B) Immunohistochemical HER3 scores of tumor tissue of responders to PD-1 inhibitor treatment.

Α